Company news
Tiziana Life Sciences Ltd (NASDAQ:TLSA) news
Every Tiziana Life Sciences Ltd press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Telos Corporation Expands Cyber Risk Management Support for the National Archives and Records Administration
September 8, 2026
Telos Corporation Expands Cyber Risk Management Support for the Office of Naval Intelligence
September 3, 2026
Telos Corporation Awarded $34.3 Million Task Order to Support the Air Force Intelligence Community
August 31, 2026
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
August 24, 2026
Telos Corporation Announces Second Quarter 2026 Earnings
August 10, 2026
Tiziana Life Sciences : Announces Purchase of Shares by Chief Executive Officer
August 6, 2026
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
July 31, 2026
Telos Corporation Awarded Contract to Support U.S. Air Force Distributed Common Ground System Mission
July 9, 2026
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
June 15, 2026
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
May 28, 2026
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
May 21, 2026
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
May 19, 2026
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
May 14, 2026
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflam...
April 16, 2026
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
April 14, 2026
Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
April 1, 2026
Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pa...
February 25, 2026
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
January 20, 2026
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
January 16, 2026
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
January 16, 2026
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Fra...
January 9, 2026
Tiziana Life Sciences Files Annual Safety Report for Intranasal Foralumab with FDA
December 30, 2025
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
December 29, 2025
Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
December 19, 2025
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
December 17, 2025
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial
December 17, 2025
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
December 15, 2025
Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering
December 15, 2025
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial
December 12, 2025
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
December 2, 2025
Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
November 25, 2025
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
November 13, 2025
Aquestive Therapeutics Announces Leadership Expansion to Support Growth
November 4, 2025
Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
October 29, 2025
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
September 30, 2025
Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
September 25, 2025
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
September 24, 2025
Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
September 15, 2025
Tiziana Life Sciences Announces Purchase of Shares by Chairman
September 5, 2025
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
August 14, 2025
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
August 11, 2025
Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient
July 21, 2025
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell M...
June 13, 2025
Tiziana Life Sciences to Present at the Bio International Convention
June 13, 2025
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
May 23, 2025
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease
May 15, 2025
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with In...
May 9, 2025
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
May 6, 2025
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
April 23, 2025
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
April 2, 2025